Posts

Posted on

ICICI Bank Canada Visa* Debit Card launched

ICICI Bank Canada Visa* Debit Card launched

  • The card enables customers to shop online and at merchant outlets across the world on Visa network
  • Allows quick contactless payments at PoS machines across the country

TORONTO–(BUSINESS WIRE)–
ICICI Bank Canada today announced the launch of a debit card. Named, ‘ICICI Bank Canada Visa Debit Card’, it offers customers an unparalleled benefit of online shopping, purchasing at millions of retail outlets across the world and making quick contactless payments at Point of Sale (PoS) machines across Canada. This card also empowers customers to withdraw cash from thousands of Automated Banking Machines (ABMs) in the country without surcharge#.

Further, the Bank offers customers the ease of activating the card and blocking/unblocking it with a few simple clicks on its mobile banking app, ‘ICICI Bank Canada iMobile app’ and online banking platform. It is the first card in Canada that enjoys the combined strength of Visa*,Interac† and THE EXCHANGE® Network as it is powered by these three large networks.

Commenting on the launch, Mr. Sandeep Goel, President and CEO, ICICI Bank Canada, said, “At ICICI Bank Canada, it is our constant endeavor to bring forth innovative banking solutions for our customers. We are delighted to join hands with our long standing partner Visa for the launch of this unique debit card. During the ongoing pandemic, we are witnessing an accelerated shift of consumers towards the digital world, resulting in record growth in online sales. We believe that this card will act as an enabler to provide our customers with a frictionless payment experience across channels.”

ICICI Bank Canada and Everlink Payment Services Inc. are jointly spearheading the Visa debit card adoption for other financial institutions to drive digital payments growth in Canada.

“We are pleased to work with ICICI Bank Canada to offer its customers increased choice, flexibility and security through access to Visa’s leading debit capabilities,” said Ms.Stacey Madge, President & Country Manager, Visa Canada. “As spending habits continue to show a preference for online shopping, customers of ICICI Bank Canada will now have more ways to shop online with ‘ICICI Bank Canada Visa Debit Card’, accepted by millions of merchants worldwide.”

“It has been a pleasure to work with ICICI Bank Canada to bring ‘ICICI Bank Canada Visa Debit Card’ to market and we’re very excited about the benefits this program will bring,” said Mr.Mark Ripplinger, President and CEO of Everlink. “We feel the delivery of this program is apt in time amidst the challenges of the COVID-19 pandemic. Indeed, over the last few years we have witnessed the rapid shift in card payments from brick and mortar stores to online. This has only been accelerated over the last eight months as cardholders seek safer ways to shop.”

“We are excited to see ICICI Bank Canada take the lead in offering this first-to-market service to their customers. THE EXCHANGE Network saves Canadian cardholders millions of dollars each year in ABM surcharge fees and we are thrilled that our longstanding member, ICICI Bank Canada, is extending our unique network value to its ICICI Bank Canada Visa Debit Card cardholders,” said Mr. Andrew Obee, President & CEO of FICANEX.

Key benefits of the card:

Worldwide acceptance: Customers can use the card to shop online at more than 1.5 million merchants and at 55 million international retailers worldwide, wherever Visa is accepted.

Robust security: Robust Visa security measures and 24×7 fraud monitoring make the online transactions even more safe and secure.

Manage cards feature: This feature enables customers to activate the card or block/unblock it digitally, using ICICI Bank Canada iMobile app and online banking platform.

PoS and ABMs: The card can be used at more than 450,000 PoS locations in Canada and offers surcharge-free access to thousands of ABM machines in the country#.

An existing customer of the Bank can apply for this card by visiting any ICICI Bank Canada branch or contacting the customer contact center.

To learn more about the ICICI Bank Canada Visa Debit Card, please click here.

About ICICI Bank Canada

ICICI Bank Canada is a wholly-owned subsidiary of ICICI Bank Limited, which has its headquarters in Mumbai, India. ICICI Bank Limited (BSE: ICICIBANK, NSE: ICICIBANK and NYSE: IBN) is a leading private sector bank in India. The Bank’s consolidated total assets stood at US$200.08 billion as at September 30, 2020. Active in all provinces and territories, ICICI Bank Canada conducts business as a full service direct bank under Canada’s Bank Act. Visit icicibank.ca to learn more

About Visa Inc.

Visa Inc. (NYSE: V) is a world leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network – enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. Our relentless focus on innovation is a catalyst for the rapid growth of digital commerce on any device for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit visa.ca, usa.visa.com/visa-everywhere/blog.html and @VisaCA.

*VISA is a registered trademark of Visa International Service Association and used under license

†Interac and Interac Flash are registered trademark owned by Interac Corp.., used under license

®THE EXCHANGE marks are licensed for use in Canada by FICANEX Services Limited Partnership

# Surcharge free withdrawals only on THE EXCHANGE Network

Shweta Patheja

ICICI Bank Canada

+1 (416) 885 2994

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Other Professional Services Professional Services Technology Online Retail Consumer Other Consumer Retail Other Technology

MEDIA:

Logo
Logo
Posted on

Clean Energy and Total to Develop Additional Carbon-Negative Fuel and Infrastructure

Clean Energy and Total to Develop Additional Carbon-Negative Fuel and Infrastructure

Up to $145 Million Available for Upstream Renewable Natural Gas Projects and Downstream Fueling

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–
Clean Energy Fuels Corp. (Nasdaq: CLNE) and its largest shareholder, Total S.E., today announced a memorandum of understanding to create a 50/50 joint venture to develop carbon-negative renewable natural gas (RNG) production facilities in the United States, as well as credit support to build additional downstream RNG fueling infrastructure. Total will provide $50 million and Clean Energy $30 million for the proposed joint venture and Total will be providing credit support of $65 million to support Clean Energy development in the RNG value chain, including $45 million for contracted RNG fueling infrastructure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005177/en/

The companies have already partnered to expand the use of RNG in the heavy-duty truck market with its Zero Now program, which allows fleets to purchase natural gas trucks for the same price as diesel trucks. The demand for carbon-negative RNG, which is derived from dairies and other agricultural facilities, has rapidly accelerated through the Zero Now program with trucking companies such as Kenan Advantage, KeHE Distributors, Estes Express Lines, Tradelink Transport, among many others, taking advantage of the economic savings while powering their new fleets with the cleanest fuel in the world.

Negative-carbon RNG is produced when carbon emissions are captured from dairies and turned into a transportation fuel, reducing the harmful effects on long-term climate change. As a result, the California Air Resources Board gives these carbon-negative RNG projects a carbon intensity (“CI”) Score (gCO2e/MJ) of -250 (or lower) compared to 97 for diesel and 46 for electric batteries. Clean Energy is the largest provider of RNG as a transportation fuel in the United States and Canada, and the largest RNG fuel provider under the California LCFS program.

“We are very fortunate to have a partner in Total that is so supportive on a number of levels,” said Andrew J. Littlefair, CEO and president of Clean Energy. “Both our companies have recognized the enormous opportunity that a carbon-negative fuel can play in our ambitious efforts to combat climate change. This new agreement will allow Clean Energy to increase the flow of low-CI RNG as the demand expands, as well as the capital to build new fueling stations for additional contracted fleets.”

Clean Energy’s goal is to meet the rapidly growing demand by customers for carbon-negative RNG and to deliver 100% Redeem™ branded RNG to its entire fueling infrastructure by 2025, which it is well on its way to achieving.

About Clean Energy

Clean Energy Fuels Corp. is the leading provider of the cleanest fuel for the transportation market in the United States and Canada. Through its sales of Redeem™ renewable natural gas (RNG), which is derived from capturing biogenic methane produced from decomposing organic waste, Clean Energy allows thousands of vehicle fleets, from airport shuttles to city buses to waste and heavy-duty trucks, to reduce their amount of climate-harming greenhouse gas by at least 70% and even up to 300% depending on the source of the RNG. Clean Energy can deliver Redeem through compressed natural gas (CNG) and liquified natural gas (LNG) to its network of approximately 540 fueling stations across the U.S. and Canada. Clean Energy builds and operates CNG and LNG fueling stations for the transportation market, owns natural gas liquefication facilities in California and Texas, and transports bulk CNG and LNG to non-transportation customers around the U.S. For more information, visit www.CleanEnergyFuels.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks, uncertainties and assumptions, such as statements regarding, among other things: the completion and timing of the transaction contemplated by the Memorandum of Understanding (“MOU”); Clean Energy’s plans for its RNG business; increased market adoption of carbon-negative RNG as a vehicle fuel; growth in Clean Energy’s customer base for its Redeem™ RNG vehicle fuel; the strength of Clean Energy’s vehicle fueling infrastructure and its ability to leverage this infrastructure to increase sales of Redeem™ vehicle fuel and to deliver 100% Redeem™ branded RNG to its entire fueling infrastructure by 2025; the benefits of RNG as an alternative vehicle fuel, including economic and environmental benefits; and growth in and certainty of supply of RNG. Actual results and the timing of events could differ materially from those expressed in or implied by these forward-looking statements as a result of a variety of factors, including, among others: Clean Energy’s and TOTAL’S ability to close the joint venture contemplated by the MOU on the timeline anticipated or at all; supply, demand, use and prices of crude oil, gasoline, diesel, natural gas and alternative fuels, as well as heavy-duty trucks and other vehicles powered by these fuels; the willingness of fleets and other consumers to adopt RNG as a vehicle fuel; and general economic, political, regulatory, market and other conditions. The forward-looking statements made in this press release speak only as of the date of this press release and Clean Energy undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Additionally, the reports and other documents Clean Energy files with the SEC (available at www.sec.gov) contain additional information on these and other risk factors that may cause actual results to differ materially from the forward-looking statements contained in this press release.

Clean Energy Contact:

Raleigh Gerber

949-437-1397

[email protected]

Investor Contact:

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Environment Alternative Vehicles/Fuels Trucking Automotive Transport Oil/Gas Automotive Manufacturing Manufacturing Energy Fleet Management

MEDIA:

Logo
Logo
Logo
Logo
Posted on

UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma

UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma

Initiation of innovative clinical trial focused on reducing complications and enhancing patient recovery following trauma at Memorial Hermann-Texas Medical Center, a major Level 1 Trauma Center, with funding from MTEC

CLEVELAND–(BUSINESS WIRE)–
The University of Texas Health Science Center at Houston (UTHealth) and Athersys, Inc. (NASDAQ: ATHX) announced today that the first patient has been enrolled in a clinical study evaluating MultiStem® cell therapy for the potential early treatment of traumatic injuries and the subsequent complications that result. The MATRICS-1 (MultiStem Administration for Trauma Related Inflammation and Complications) study is being conducted at Memorial Hermann-Texas Medical Center, one of the busiest Level 1 trauma centers in the United States.

The Phase II randomized, double-blinded, placebo-controlled study is being funded by a grant award from the Medical Technology Enterprise Consortium (MTEC) awarded to McGovern Medical School at UTHealth. In addition, the Memorial Hermann Foundation is providing additional funding. Athersys is the trial sponsor and is supplying the investigational clinical product for the conduct of the trial, as well as providing regulatory and operational support. Dr. Charles S. Cox Jr., the George and Cynthia Mitchell Distinguished Chair in Neurosciences in the Department of Pediatric Surgery at McGovern Medical School at UTHealth and co-Director of the Red Duke Trauma Institute at Memorial Hermann-Texas Medical Center, is serving as the principal investigator.

The objective of the clinical study is to evaluate the safety and efficacy of MultiStem in the treatment of injured patients with severe hemorrhage for the prevention and mitigation of complications that can result following severe traumatic injury. The single-center trial will enroll up to 156 subjects. Subjects will be randomized and administered either placebo or MultiStem cellular therapy following admission to the intensive care unit and after initial resuscitation has concluded and stabilizing procedures have been performed to stop bleeding. All study subjects will also receive all standard of care treatments for their injuries.

“The use of this treatment strategy leverages a long legacy of investigation into the common mechanism of action of down-regulation of the inflammatory response to injury and how it mitigates complications of trauma,” commented Dr. Charles S. Cox Jr., Principal Investigator at UTHealth.

Although the causes of traumatic injury are diverse, evidence suggests the hyperinflammatory response following these injuries is similar to other causes of acute tissue injury, such as acute ischemic stroke, acute respiratory distress syndrome (ARDS), traumatic brain injury and spinal cord injury. Activation and mobilization of the peripheral immune system after an injury contributes to local secondary tissue damage. This immune activation may also result in systemic inflammatory response syndrome (SIRS), which can leave the patient susceptible to a range of complications, including secondary infections and organ failure conditions, that prevent or complicate recovery. Results of pre-clinical injury models and clinical data from human trials in other indications suggest early administration of MultiStem cells may reduce the inflammatory cascade that ensues after severe acute injury by reducing the number of inflammatory systemic immune cells in and around sites of injury, and by decreasing immune cell activation and the release of inflammatory cytokines in response to circulating products of tissue injury. The study will evaluate whether MultiStem’s modulation of these immune responses to traumatic injury can mitigate secondary tissue injury, organ failure states, and other complications that impede patient recovery following severe traumatic injury.

“Prior research conducted in collaboration with UTHealth suggests that administration of MultiStem following traumatic injury has the potential to downregulate the resultant hyperinflammatory cascade, and upregulate key repair mechanisms, improving overall recovery. Athersys is very appreciative of the support provided by MTEC and the Memorial Hermann Foundation for the conduct of this study and the tremendous amount of hard work and effort we’ve experienced in this collaboration with researchers, clinicians and staff at UTHealth,” commented Dr. Robert W. Mays, Vice President of Regenerative Medicine and Head of Neuroscience Programs at Athersys. “We are pleased to enroll the first patient and look forward to evaluating the effects of MultiStem cellular therapy on patient outcomes. Severe trauma and the related downstream pathologies it can initiate is a clear unmet medical need of significance.”

According to the Centers for Disease Control (CDC), trauma is the leading cause of death for individuals under the age of 45 and the third leading cause of death in the U.S., accounting for approximately 180,000 fatalities each year. It is also a leading cause of serious disability, especially among young people and members of the military that suffer trauma. According to independent research there are more than 31 million non-fatal injuries treated in U.S. hospitals each year.1

Athersys released an educational video today to provide additional information about this first-ever clinical study evaluating a cell therapy for treatment of traumatic injuries. The video features interviews with the clinical investigators that will be participating in the trial and other key personnel at Athersys. The video may be assessed from the Athersys website at www.athersys.com or at the following YouTube link: https://youtu.be/qyxn2Z78aW0

1Zonfrillo, M.R., Spicer, R.S., Lawrence, B.A. et al. Incidence and costs of injuries to children and adults in the United States. Inj. Epidemiol. 5,37 (2018). https://doi.org/10.1186/s40621-018-0167-6

About MultiStem®

MultiStem® cell therapy is a patented regenerative medicine product candidate in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy’s potential for multidimensional therapeutic impact may distinguish it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. MultiStem represents a unique “off-the-shelf” stem cell product candidate that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon favorable outcome data, its novel mechanisms of action, and favorable and consistent tolerability data in clinical studies, we believe that MultiStem therapy may provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.

About MTEC

MTEC is a biomedical technology consortium collaborating with multiple government agencies under an agreement with the U.S. Army Medical and Materiel Command. The MTEC mission is to assist the Army’s Medical Research and Materiel Command by providing cutting-edge technologies and effective materiel life cycle management to transition medical solutions to industry.

About UTHealth

Established in 1972 by The University of Texas System Board of Regents, The University of Texas Health Science Center at Houston (UTHealth) is Houston’s Health University and Texas’ resource for health care education, innovation, scientific discovery and excellence in patient care. The most comprehensive academic health center in the UT System and the U.S. Gulf Coast region, UTHealth is home to Jane and Robert Cizik School of Nursing, John P. and Kathrine G. McGovern Medical School, and schools of biomedical informatics, biomedical sciences, dentistry, and public health. UTHealth includes the UTHealth Harris County Psychiatric Center, as well as the growing clinical practices UT Physicians, UT Dentists, and UT Health Services. The university’s primary teaching hospitals are Memorial Hermann-Texas Medical Center, Children’s Memorial Hermann Hospital, and Harris Health Lyndon B. Johnson Hospital. For more information, visit www.uth.edu.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “suggest,” “will,” or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face are the risks and uncertainties inherent in the process of discovering, developing, and commercializing products that are safe and effective for use as therapeutics, including the uncertainty regarding market acceptance of our product candidates and our ability to generate revenues. The following risks and uncertainties may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements: our ability to raise capital to fund our operations, including but not limited to, our ability to access our traditional financing sources on the same or reasonably similar terms as were available to us before the COVID-19 pandemic; the timing and nature of results from MultiStem clinical trials, including the MASTERS-2 Phase 3 clinical trial evaluating the administration of MultiStem for the treatment of ischemic stroke, and the Healios TREASURE and ONE-BRIDGE clinical trials in Japan evaluating the treatment in stroke and ARDS patients, respectively; the success of our MACOVIA clinical trial evaluating the administration of MultiStem for the treatment of COVID-19 induced ARDS, and the MATRICS-1 clinical trial being conducted with The University of Texas Health Science Center at Houston evaluating the treatment of patients with serious traumatic injuries; the impact of the COVID-19 pandemic on our ability to complete planned or ongoing clinical trials; the possibility that the COVID-19 pandemic could delay clinical site initiation, clinical trial enrollment, regulatory review and the potential receipt of regulatory approvals, payment of milestones under our license agreements and commercialization of one or more of our product candidates, if approved; the availability of product sufficient to meet commercial demand shortly following any approval, such as in the case of accelerated approval for the treatment of COVID-19 induced ARDS; the impact on our business, results of operations and financial condition from the ongoing and global COVID-19 pandemic, or any other pandemic, epidemic or outbreak of infectious disease in the United States; the possibility of delays in, adverse results of, and excessive costs of the development process; our ability to successfully initiate and complete clinical trials of our product candidates; the impact of the COVID-19 pandemic on the production capabilities of our contract manufacturing partners and our MultiStem trial supply chain; the possibility of delays, work stoppages or interruptions in manufacturing by third parties or us, such as due to material supply constraints, contamination, operational restrictions due to COVID-19 or other public health emergencies, labor constraints, regulatory issues or other factors which could negatively impact our trials and the trials of our collaborators; uncertainty regarding market acceptance of our product candidates and our ability to generate revenues, including MultiStem cell therapy for neurological, inflammatory and immune, cardiovascular and other critical care indications; changes in external market factors; changes in our industry’s overall performance; changes in our business strategy; our ability to protect and defend our intellectual property and related business operations, including the successful prosecution of our patent applications and enforcement of our patent rights, and operate our business in an environment of rapid technology and intellectual property development; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; our ability to meet milestones and earn royalties under our collaboration agreements, including the success of our collaboration with Healios; our collaborators’ ability to continue to fulfill their obligations under the terms of our collaboration agreements and generate sales related to our technologies; the success of our efforts to enter into new strategic partnerships and advance our programs, including, without limitation, in North America, Europe and Japan; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; the success of our competitors and the emergence of new competitors; and the risks mentioned elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2019 under Item 1A, “Risk Factors” and our other filings with the SEC. You should not place undue reliance on forward-looking statements contained in this press release, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Ivor Macleod

Chief Financial Officer

Tel: (216) 431-9900

[email protected]

Karen Hunady

Director of Corporate Communications & Investor Relations

Tel: (216) 431-9900

[email protected]

David Schull

Russo Partners, LLC

Tel: (212) 845-4271 or (858) 717-2310

[email protected]

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Health Clinical Trials Research Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo
Posted on

Institutional Property Advisors Closes Two-Property $90.2 Million Multifamily Portfolio Sale in Southern Arizona

Institutional Property Advisors Closes Two-Property $90.2 Million Multifamily Portfolio Sale in Southern Arizona

TUCSON, Ariz.–(BUSINESS WIRE)–Institutional Property Advisors (IPA), a division of Marcus & Millichap (NYSE: MMI), announced today the sale of a two-property multifamily portfolio in Tucson, Arizona. The properties are Equestrian, a 288-unit complex that sold for $47.7 million, or $165,625 per unit, and Ridgeline, a 272-unit property that traded for $42.5 million, which represents $156,250 per unit.

“Post-2000 constructed multifamily assets like Equestrian and Ridgeline are rarely available in North Tucson,” said Hamid Panahi, IPA first vice president. “These two communities provide new ownership with the opportunity to enhance revenue through the continued implementation of an apartment interior renovation program.” Panahi, along with Steve Gebing and Cliff David, IPA executive managing directors, represented the seller, Bascom Arizona Ventures, and procured the buyer, Bridge Investment Group. “Job growth and economic development should not be overlooked in Tucson with tremendous momentum in the aerospace and defense sector, high technology, bioscience, healthcare, mining technology, and logistics leading the way,” added Gebing. “There’s a reason internationally recognized companies like Raytheon, Caterpillar, and Amazon are attracted to the market.”

Both properties are located on West Linda Vista Boulevard in Northwest Tucson, close to Thornydale Retail Center, Thornydale Village, Tucson Premium Outlets and Pima Community College. Completed in 2008 on 13 acres, Equestrian has 18 residential buildings, a swimming pool, gas and charcoal grilling stations, assigned covered parking and detached garages. Apartments have nine-foot ceilings and the average unit size is 900 square feet. Ridgeline’s 17 residential buildings were constructed in 2002 and 2008 on 13 acres. The property has two resort-style swimming pools and the average apartment size is 821 square feet.

About Institutional Property Advisors (IPA)

Institutional Property Advisors (IPA) is a division of Marcus & Millichap (NYSE: MMI), a leading commercial real estate services firm in North America. IPA’s combination of real estate investment and capital markets expertise, industry-leading technology, and acclaimed research offer customized solutions for the acquisition, disposition and financing of institutional properties and portfolios. For more information, please visit www.institutionalpropertyadvisors.com.

About Marcus & Millichap, Inc.

With over 2,000 investment sales and financing professionals located throughout the United States and Canada, Marcus & Millichap is a leading specialist in commercial real estate investment sales, financing, research and advisory services. Founded in 1971, the firm closed 9,726 transactions in 2019 with a value of approximately $50 billion. Marcus & Millichap has perfected a powerful system for marketing properties that combines investment specialization, local market expertise, the industry’s most comprehensive research, state-of-the-art technology, and relationships with the largest pool of qualified investors. For additional information, please visit www.MarcusMillichap.com.

Gina Relva

Public Relations Director, Marcus & Millichap

510-999-1284

KEYWORDS: Arizona United States North America

INDUSTRY KEYWORDS: Residential Building & Real Estate Commercial Building & Real Estate Construction & Property

MEDIA:

Logo
Logo
Posted on

Insulet to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

Insulet to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

ACTON, Mass.–(BUSINESS WIRE)–
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 12, 2021 at 9:10 a.m. (Eastern Time)

To listen to the live audio webcast of the presentation, please visit http://investors.insulet.com. A replay of the audio webcast will also be available following the event.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: www.insulet.com and www.myomnipod.com.

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations

(978) 600-7717

[email protected]

Jason McGorman

Principal Investor Relations Analyst

(978) 600-7627

[email protected]

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Medical Devices Health Diabetes General Health Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

Tower Semiconductor and GMEMS Announce the Ramp to Mass Production of MEMS Microphones Products

                                                                                                 



 



Based on Tower’s flow in its high volume 200mm CMOS Fab, custom developed for GMEMS products enabling capacity expansion for high volume manufacturing





MIGDAL HAEMEK, Israel, and MILPITAS, California, December 21, 2020 – Tower Semiconductor (NASDAQ/TASE: TSEM), the leader in high-value analog semiconductor foundry solutions, and GMEMS, a supplier of MEMS (Micro-Electro-Mechanical Systems) sensors and products to the telecommunications industry , today announced the ramp to mass production of GMEM’s MEMS microphones products on Tower’s 0.18um flow, custom developed for GMEMS products. Tailor designed for the rapidly growing demand of the earbuds and cellphone markets, GMEMS’s highly advanced microphones offer a substantially smaller solution than competition. Utilizing Tower’s advanced facilities and platforms provides high volume manufacturing and capacity assurance, enabling to meet these fast-growing market demands.

According to Yole Development, MEMS microphone market is expected to grow from $1.2B (5.8B units) in 2019 to $1.7B (9.3B units) in 2024 with 6.6% CAGR.

“We are very pleased to have partnered with Tower to enhance the manufacturing capability for our highly demanded microphone products. We chose Tower for its excellent reputation, superior technical capabilities, advanced technology platforms and its capability to manufacture MEMS at large scale due to the compatibility with its CMOS flow,” said Dr. Mark Wang, GMEMS CEO.  “The joint effort between GMEMS experts and Tower’s exceptional R&D team enabled a successful ramp to a stable high volume manufacturing of our products, as well as to set a roadmap for the development of our next-generation microphones“.

In addition to a very small die size, Tower’s flow offers multiple advantages for the manufacturing of the MEMS microphones including high dynamic range and high SNR (Signal to Noise Ratio), key features when addressing MEMS microphone market demands, especially for mobile devices.

“We are excited about our cooperation with GMEMS, a world leading company in its field, developing outstanding technology solutions and products. Our tight and well-aligned collaboration allowed to effectively ramp GMEMS excellent products to high volume mass production using best in class technology,” said Dr. Avi Strum, Senior Vice President and General Manager of Sensors & Displays Business Unit, Tower Semiconductor. “We look forward to accomplishing additional achievements together allowing to realize even greater market potential”.

For more information about Tower Semiconductor’s MEMS technology platform, please click here.

For more information about Tower Semiconductor’s process technology offerings, please click here or inquire at: [email protected]

For more information about GMEMS technology and products, please click here.

About GMEMS

GMEMS is a leading developer and provider of MEMS microphones, voice interface software and other MEMS products. With its core technical team having accumulated more than twenty years of working experience in MEMS acoustic sensor and noise suppression algorithms, GMEMS provides a one-stop solution for its end customers. Over the years, GMEMS has established itself as a leader in providing high performance MEMS microphones and voice processing algorithms for voice interface applications in telecommunication industry.

About Tower Semiconductor

Tower Semiconductor Ltd. (NASDAQ: TSEM, TASE: TSEM), the leader in high-value analog semiconductor foundry solutions, provides technology and manufacturing platforms for integrated circuits (ICs) in growing markets such as consumer, industrial, automotive, mobile, infrastructure, medical and aerospace and defense. Tower Semiconductor’s focuses on creating positive and sustainable impact on the world through long term partnerships and its advanced and innovative analog technology offering, comprised of a broad range of customizable process platforms such as SiGe, BiCMOS, mixed-signal/CMOS, RF CMOS, CMOS image sensor, non-imaging sensors, integrated power management (BCD and 700V), and MEMS. Tower Semiconductor also provides world-class design enablement for a quick and accurate design cycle as well as Transfer Optimization and development Process Services (TOPS) to IDMs and fabless companies. To provide multi-fab sourcing and extended capacity for its customers, Tower Semiconductor operates two manufacturing facilities in Israel (150mm and 200mm), two in the U.S. (200mm) and three facilities in Japan (two 200mm and one 300mm) through TPSCo. For more information, please visit www.towersemi.com.

Safe Harbor Regarding Forward-Looking Statements

This press release includes forward-looking statements, which are subject to risks and uncertainties. Actual results may vary from those projected or implied by such forward-looking statements. A complete discussion of risks and uncertainties that may affect the accuracy of forward-looking statements included in this press release or which may otherwise affect Tower’s business is included under the heading “Risk Factors” in Tower’s most recent filings on Forms 20-F, F-3, F-4 and 6-K, as were filed with the Securities and Exchange Commission (the “SEC”) and the Israel Securities Authority. Tower does not intend to update, and expressly disclaim any obligation to update, the information contained in this release. 

###

Tower Semiconductor Company Contact: Orit Shahar | +972-74-7377440 | [email protected]

Tower Semiconductor Investor Relations Contact: Noit Levy | +972-4-604-7066 | [email protected]

Attachment



Posted on

Tanzanian Gold Announces the Sale of $2,993,390 of Common Shares and Warrants

VANCOUVER, British Columbia, Dec. 21, 2020 (GLOBE NEWSWIRE) — Tanzanian Gold Corporation’s (TSX:TNX) (NYSE American:TRX) (the “Company’s”) Board of Directors is pleased to announce the entering into subscription agreements for the sale of 5,545,325 common shares and warrants to purchase 2,772,637 common shares raising in $2,993,390 in the aggregate with certain investors. The common shares and warrants were sold at a fixed combination price of $0.5398 for each common share and a one-half purchase warrant with the right of each whole warrant to purchase one common share at $1.50 for a period of three years.

The proceeds from the sale of common shares and warrants will be used for capital expenditures, continued exploration, general corporate purposes and working capital.

The common shares and warrants, and common shares underlying the warrants, are being offered pursuant to an effective shelf registration statement on Form F-3, which was previously filed with the Securities and Exchange Commission and declared effective on November 25, 2020. The sale of the common shares and warrants is expected to close on or around December 23, 2020, subject to the satisfaction of customary closing conditions, including acceptance of the listing of the common shares by the NYSE American and the Toronto Stock Exchange.

Respectfully Submitted,

“James E. Sinclair”

James E. Sinclair

Executive Chairman

For further information, please contact Michael Martin, Investor Relations, [email protected], 860-248-0999, or visit the Company website at www.tanzaniangoldcorp.com

Cautionary Note Regarding Forward-looking Statements

Certain of the statements made herein may contain forward-looking statements or information within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Often, but not always, forward- looking statements and forward-looking information can be identified using words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, ,occur or be achieved. Forward-looking statements or information herein include, but are not limited to that the sale of the common shares and warrants will be completed.

Forward-looking statements and forward-looking information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. We have made certain assumptions about the forward-looking statements and information and even though our management believes that the assumptions made and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking statement or information will prove to be accurate. Furthermore, should one or more of the risks, uncertainties or other factors materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements or information. These risks, uncertainties and other factors include, among others, the following: gold price volatility; discrepancies between actual and estimated production, mineral reserves and resources and metallurgical recoveries; mining operational and development risk; litigation risks; regulatory restrictions, including environmental regulatory restrictions and liability; risks of sovereign investment; currency fluctuations; speculative nature of gold exploration; global economic climate; dilution; share price volatility; competition; loss of key employees; additional funding requirements; and defective title to mineral claims or property, as well as those factors discussed in the sections entitled “Forward-Looking Statements” and “Risk Factors” in the Company’s Form 20-F Annual Report for the year ended August 31, 2020. .

There can be no assurance that forward-looking statements or information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, you should not place undue reliance on the forward-looking statements or information contained herein. Except as required by law, we do not expect to update forward- looking statements and information continually as conditions change and you are referred to the full discussion of the Company’s business contained in the Company’s reports filed with the securities regulatory authorities in Canada and the U.S.



Posted on

Loop Insights Launches Digital Connect Health Platform, A Fully-Integrated Digital Healthcare Solution For Governments, After Extended Discussions With Provinces, Federal Government and Private Sector

Loop Digital Connect Health Platform Will Provide Provincial and Federal Healthcare Systems The Ability To Connect Current Siloed Legacy and Antiquated Systems

VANCOUVER, British Columbia, Dec. 21, 2020 (GLOBE NEWSWIRE) — Loop Insights Inc. (MTRX:TSXV) (RACMF:OTCQB) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick and mortar space, is pleased to announce the January 2021 launch of its Digital Connect Health Platform, a fully-integrated digital healthcare solution designed for both government and private sector. The launch comes after continuous discussions and requests from government leaders, both Provincial and Federal, over the past 7 months.

On April 20th, Loop Insights launched the Beta version of its Smart Health contactless check-in platform, which streamlines patient engagement and operations. Loop’s Smart Health device requires a simple tap of the patient’s mobile phone to check in and verify their ID. Patients have frictionless access to everything they need in one simple wallet pass, including real-time notifications, testing and tracing updates, critical health information, and more.

MOVING FROM BETA VERSION TO MARKET READY

Following ongoing conversations with stakeholders at the highest levels of government, as well as private markets, Loop Insights will integrate its real-time AI-driven data applications with its IoT solutions and digital wallet to create its Digital Connect Health Platform, which provides governments and private clients with the following:

  •  A secure Digital ID
  •  Integrated data functionality
  •  Easy access to medical records
  •  Integrated eCommerce

Loop’s Digital Connect Health Platform is regarded as a customized platform per government specifications.

BRIDGING THE HEALTHCARE JURISDICTIONAL DIVIDE TO DELIVER CONNECTIVITY NEVER BEFORE THOUGHT POSSIBLE

The attempted implementation of wildly varying COVID-19 medical and security protocols, as well as, restriction policies by health officials and government leaders from around the world, has clearly demonstrated how divided government leaders have become by jurisdictional lines due to the lack of a single platform capable of providing uniformity and consistency in the application of policies. Recognizing this breakdown, in conjunction with input from those same government leaders, Loop Insights developed the Digital Connect Health Platform to be capable of connecting Provincial and Federal systems while allowing Provinces to fully maintain their jurisdictional authority by managing their own internal data repositories.

Specifically, the Loop Digital Connect Health Platform sits on top of each Provincial (or State) system to aggregate and connect information into a Data Warehouse. This continuity across all platforms delivers the ultimate goal health leaders have always wanted, never thought possible but requested from Loop Insights – the ability for Provincial healthcare systems to speak to each other. Of the many benefits of having this platform, the simplest and most powerful is the ability for citizens to be away from their home province while using a singular platform to deliver the best healthcare possible.

Loop Insights CEO Rob Anson stated “This has been nothing short of a massive undertaking over the past 7 months. In conjunction with key stakeholders who have been expressing the need for continued digital transformation within the healthcare sector, we have delivered a complete end-to-end digital solution that solves the challenge of decades of siloed data, a lack of connectivity, and a lack of access. As a result, Loop provides governments and the private sector with the ability to connect their current legacy and antiquated systems. This is so revolutionary that it has attracted the attention of global technology companies and has positioned Loop for success within healthcare.”

CANADIAN HEALTHCARE INDUSTRY PROVIDE SIGNIFICANT OPPORTUNITY, PRESENTATIONS ALREADY COMMENCED THROUGHOUT NORTH AMERICA AND EUROPE

With provinces such as Ontario experimenting with the potential of digital wallet applications, Loop Insights sees a significant opportunity to provide a solution to the Canadian healthcare industry in particular. With individual Provinces considering a digital healthcare solution, a federal platform will require a fully-integrated solution that allows for secure electronic medical records, third-party billing services, and extended healthcare services.

According to IBISWorld, the Canadian healthcare industry represents a $74-billion market opportunity, with over 1200 businesses working in the space. Loop Insights has developed a smart health platform that will provide a gateway for these siloed platforms to work together, allowing for safe and secure collaboration between multiple large scale healthcare systems.

In addition to its business development progress in the Canadian healthcare industry, Loop Insights has presented to leading healthcare companies in North America and Europe.

LOOP DIGITAL WALLET HEALTHCARE APPLICATION WILL PROVIDE SAFE AND SECURE PATIENT CONNECTIVITY TO GO BEYOND COVID-19

In order to improve the lives of patients, Loop Insights’ digital healthcare wallet platform will provide instant medical reminders including appointments, prescription reminders, critical medical transportation services, and more. The platform will allow patients to book appointments with their family doctor or other healthcare professionals within their mobile device. In the era of social distancing, Loop Insights’ automatic queuing and notifications will allow doctors to keep their waiting rooms open while operating at full efficiency. Once at the doctor’s office or medical facility, patients will be able to tap to check-in with their smartphone, registering with their verified healthcare ID.


On December 9th, Loop Insights joined KABN Systems NA Holdings Corp. (CSE:KABN)
, Liquid Avatar, Lumedic, The Campus Agency, and TripXpertzwas to form a consortium to manage verifiable identity credentials for COVID-19 vaccinations. Through this consortium and Loop Insights’ previous partnership with iStoc, the Company is now able to provide medical testing beyond the scope of the COVID-19 pandemic.

In partnership with iStoc, Loop Insights is now offering integrated testing for:

  •  Infectious diseases
  •  Blood alcohol levels (saliva based)
  •  Women’s health screening
  •  Pregnancy
  •  Drug use
  •  Sexually-transmitted diseases
  •  Blood group testing
  •  Veterinary diseases

In order to match growing demand, Loop Insights has also worked with Istoc to launch integrated global testing solutions for:

  • HIV
  • Malaria
  • Dengue
  • Hepatitis B
  • Hepatitis C
  • Tuberculosis, TB
  • Influenza, RSV, Adeno, Strep, Mycoplasma, WIDAL, RPR, Rota, Occult Blood, H Pylori AD

This Press Release Is Available On The Loop Insights Verified Forum On AGORACOM For Shareholder Discussion And Management Engagement https://agoracom.com/ir/LoopInsights/forums/discussion

About Loop Insights

Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network.

For more information, please contact:

Loop Insights Inc.   LOOP Website : www.loopinsights.ai
Rob Anson, CEO   Facebook: @ LoopInsights
T : +1 877-754-5336 Ext. 4   Twitter: @ LoopInsights
E : [email protected]   LinkedIn: @ LoopInsights


Forward-Looking Statements/Information:
 

This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

 



Posted on

Xpeng Delivers G3 Smart Electric SUV to First Customers in Norway, Stepping Up Plans for European Market

Xpeng Delivers G3 Smart Electric SUV to First Customers in Norway, Stepping Up Plans for European Market

  • Xpeng G3 is a smart EV with a range of 520km NEDC (451km WLTP)
  • Norway represents company’s first step into Europe, with plans for other markets in development
  • G3 in Norway starts at 358,000 NKr (approx. EUR 33,700 / GBP 30,300 / USD 41,000)
  • G3 offered in Norway features English language user interface
  • Norwegian version G3 featured in the debut ‘Premiere’ episode of leading EV channel Fully Charged Show on Sunday 20 December

GUANGZHOU, China & OSLO, Norway–(BUSINESS WIRE)–
Xpeng Inc. (“Xpeng” or the “Company”, NYSE: XPEV), a leading Chinese smart electric vehicle company,has started delivery of smart EVs to customers in Norway. 100 Xpeng G3 smart electric SUVs are being handed over to their new owners this week across 28 cities and towns in Norway – the northernmost of which is Bodø (67°N), just north of the Arctic Circle.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005331/en/

Xpeng G3 Smart EV SUV (Photo: Business Wire)

Xpeng G3 Smart EV SUV (Photo: Business Wire)

While the domestic Chinese market remains its primary customer base, Xpeng is now well positioned to develop its international strategy with the launch of its first production model, the G3 electric SUV, in Norway. Xpeng is actively exploring opportunities in other EV-mature markets with supportive government policies, advanced EV infrastructure and high EV awareness as the top priority markets. Xpeng is also planning to launch its second production model, the P7 electric sports sedan, in Europe within the next 12 months.

He Xiaopeng, CEO & Chairman of Xpeng, commented: “This week’s customer deliveries in Norway represent a key milestone in Xpeng’s aspirations to become a truly international smart EV brand. Our launch in Europe comes just as consumers are shifting in increasingly large numbers to more sustainable personal transport, and at a tipping point where governments around the world are stepping up their zero emission efforts. We look forward to being a significant driver in accelerating that transition.”

The highly popular new energy and electric vehicle platform, Fully Charged Show YouTube channel, features the Xpeng G3 in its debut ‘Premiere’ episode. Hosted by renowned EV evangelist, Robert Llewellyn, the show provides an exclusive review of the G3 available in Norway.

The Xpeng G3

Photo & video gallery: Xpeng G3 in Norway

The G3 epitomises Xpeng’s strategy of offering advanced technologies at attractive price points. The list price for the G3 in Norway starts at 358,000 NKr (approx. EUR 33,700 / GBP 30,300 / USD 41,000).

This smart electric SUV is sharply styled, with a panoramic windscreen, and a certified range of 520km NEDC (451km WLTP). The G3 features Xpeng’s proprietary XPILOT 2.5 advanced driver assistance system. The G3’s auto parking function is able to distinguish between parallel and vertical parking spaces, as well as marked and unmarked parking spaces.

The G3 available in Norway features an English language user interface, with the AI-powered “Hi Xpeng” voice assistant, intelligent navigation and remote APP control.

The software for the XPILOT and Xmart OS operating system has been fully developed by Xpeng’s in-house R&D team, a clear example of the company’s approach to smart tech innovation.

Xpeng is uncompromising in its commitment to safety standards, with the G3 boasting a comprehensive suite of safety systems, helping it to achieve a class-best C-NCAP safety rating in China*.

Established in 2015, Xpeng launched its first production model in December 2018, and 2020 year-to-date deliveries of its smart EVs reached 21,341 units by the end of November, representing an 87% increase year-over-year. Xpeng listed on the New York Stock Exchange in August 2020, raising US$1.7 billion with a strong shareholder base including world renowned corporate and institutional investors. The Company completed its first public follow-on offering on 11 December 2020, raising US$2.5 billion.

Media information

About Xpeng Inc.

Xpeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers in China. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future.

In order to optimize its customers’ mobility experience, Xpeng develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrification/electronic architecture.

Xpeng is headquartered in Guangzhou, China, with offices in Beijing, Shanghai, Silicon Valley and San Diego. The Company’s Smart EVs are manufactured at plants in Zhaoqing and Zhengzhou, located in Guangdong and Henan provinces, respectively. For more information, please visit https://en.xiaopeng.com/.

*The Xpeng G3 Smart version completed the C-NCAP safety test in China on 13 July 2019.

Marie Cheung, Xpeng Inc.

+852 9750 5170

[email protected]

Mike Stainton, PFPR Communications

+44 (0) 7739 891040

[email protected]

KEYWORDS: Norway China Europe Asia Pacific

INDUSTRY KEYWORDS: Technology Alternative Vehicles/Fuels Women Automotive General Automotive Men Performance & Special Interest Consumer Consumer Electronics

MEDIA:

Photo
Photo
Xpeng G3 Smart EV SUV (Photo: Business Wire)
Posted on

Cyient Receives the Thales Supplier Performance Award 2020

– Recognized for “on-conformity delivery performance”

– Achieved “Class A” rating for “on-time delivery performance”

– Testament to the consistency and dedication in adhering to the highest delivery standards

PR Newswire

HYDERABAD, India, Dec. 21, 2020 /PRNewswire/ — Cyient, a global engineering and digital technology solutions company, today announced that it has received the “2020 Supplier Performance Award” from Thales. The company received the award at the Thales Virtual Annual Supplier Conference held on December 15, 2020, for achieving “on-conformity delivery performance” excellence.  

Thales issues the award annually to recognize suppliers across different categories for achieving excellence in execution. The award demonstrates Cyient’s dedication and consistent commitment to delivering value to its business partners and customers. The company also achieved a “Class A” rating for its “on-time delivery performance.”

Commenting on the recognition, Rajendra Velagapudi, Managing Director and CEO, Cyient DLM, said, “We are delighted to receive this award and are deeply appreciative of the strategic relationship between Cyient and Thales. This signifies our joint contribution toward the building of ‘Atmanirbhar Bharat’ and is a testament to the commitment and dedication of our associates and suppliers/partners. We look forward to scaling our relationship with Thales to new heights and raising the innovation bar to deliver greater efficiencies.”

Speaking on the occasion, Roque Carmona, Senior Vice-President, Group Chief Procurement Officer, Thales, said, “Cyient has been one of our trusted partners for several key initiatives including design engineering, manufacturing, and our ‘Go-to-India‘ programme. A successful partnership must adhere to the highest delivery standards and ensure performance excellence. We congratulate the Cyient team on achieving this distinction especially during the challenging times. Together we shall continue to contribute to the prestigious ‘Make in India‘ initiative of the Indian government.”    

About Cyient

Cyient (Estd: 1991, NSE: CYIENT) is a global engineering and digital technology solutions company. As a Design, Build, and Maintain partner for leading organizations worldwide, Cyient takes solution ownership across the value chain to help customers focus on their core, innovate, and stay ahead of the curve. The company leverages digital technologies, advanced analytics capabilities, domain knowledge, and technical expertise to solve complex business problems.

Cyient partners with customers to operate as part of their extended team in ways that best suit their organization’s culture and requirements. Cyient’s industry focus includes aerospace and defense, healthcare, telecommunications, rail transportation, semiconductor, geospatial, industrial, and energy.

For more information, please visit www.cyient.com
Follow news about the company at @Cyient

About Thales
Thales (Euronext Paris: HO) is a global high technology leader investing in digital and “deep tech” innovations –connectivity, big data, artificial intelligence, cybersecurity and quantum technology – to build a future we can all trust, which is vital to the development of our societies. The company provides solutions, services and products that help its customers –businesses, organisations and states – in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a basis including Gemalto over 12 months).

About Thales in India
Present in India since 1953, Thales is headquartered in Noida and has other operational offices and sites spread across Gurugram, Hyderabad, Bengaluru and Mumbai, among others. Over 1,800 employees are working with Thales and its joint ventures in India. Since the beginning, Thales has been playing an essential role in India’s growth story by sharing its technologies and expertise in Defence, Transport, Aerospace and Digital Identity and Security markets. Thales has two engineering competence centres in India – one in Delhi NCR focused on digital identity and security business and the other one in Bengaluru focused on hardware, software and systems engineering capabilities for both the civil and defence sectors, serving global needs.

For media inquiries please contact
：
Ishneet Sachdeva / Ananya Gupta
Email: [email protected] / [email protected]
Mobile: +91 – 9619194346 / 9810626206

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cyient-receives-the-thales-supplier-performance-award-2020-301196563.html

SOURCE Cyient